Why Is HUMANA INC (HUM) Stock Moving Today?

Humana (HUM) shares are moving lower today, down more than 7% in early trading, despite reporting second-quarter earnings and revenue that beat estimates. The stock opened with a significant gap down from the prior close and has traded in a narrow range since. The primary driver of the decline appears to be the company’s decision to reaffirm its full-year adjusted earnings outlook, a move that contrasted with expectations of a more optimistic revision and left some investors underwhelmed.

What Happened

Humana reported second-quarter 2026 adjusted earnings per share of $7.61, exceeding the $7.22 estimate, and revenue of $40.888 billion, beating the $40.611 billion forecast. The company also highlighted continued growth in its Medicare Advantage business. However, it maintained its full-year adjusted earnings outlook, a decision that appears to have disappointed some market participants. Unlike some of its peers, which have raised full-year guidance following strong quarterly results, Humana’s unchanged forecast may have led to a sell-off as investors recalibrated expectations. The company also announced the expansion of its board of directors, adding Paul Smith and Frederick Crawford, signaling a strategic focus on technology and financial discipline.

What The Data Shows

The intraday session began with a -7.4% gap down from the prior close of $388.71, opening at $359.80. The stock briefly touched its session high of $388.71 at 7:55 AM ET before retreating to a low of $355.00. The last trade was at $364.89 with no volume reported so far. The stock has traded within a 52-week range of $163.11 to $428.88 and has a trailing twelve-month revenue growth of 14.1%. With a P/E ratio of 41.5 and a beta of 0.72, the stock is seen as relatively stable but expensive. Recent insider and congressional activity includes multiple small purchases by members of Congress, with the most recent filing on July 21, 2026.

What To Watch

The stock is currently trading in a narrow range with no unusual options activity or short interest data provided. Investors should monitor the company’s full-year performance and any further updates on its Medicare Advantage strategy. No earnings date is provided, but coverage breadth remains at 13 stories from 10 sources in the last 36 hours.